Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.
Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria
Announces $1,500,000 Best-Efforts Non-Brokered Private Placement
Revive Announces Rights Offering to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria
Revive Therapeutics Provides Clinical and Corporate Update
Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2016